Alkem Laboratories Limited

rs,

55 06th August, 2021 The Corporate Relationship Department BSE Limited Phiroze J~ejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523 National Stock Exchange of India Limited Excha

27,314 million

ai today. Key highlights of Q1FY22 financial performance • Total Revenue from Operations was~ 27,314 million, year-on-year growth of 37.1% o o India sales were~ 19,097 million, year-on-year growth of 65

37.1%

nancial performance • Total Revenue from Operations was~ 27,314 million, year-on-year growth of 37.1% o o India sales were~ 19,097 million, year-on-year growth of 65.3% International sales were

19,097 million

venue from Operations was~ 27,314 million, year-on-year growth of 37.1% o o India sales were~ 19,097 million, year-on-year growth of 65.3% International sales were~ 7,903 million, year-on-year growth of 0.6

65.3%

on, year-on-year growth of 37.1% o o India sales were~ 19,097 million, year-on-year growth of 65.3% International sales were~ 7,903 million, year-on-year growth of 0.6% • Earnings before Interest

7,903 million

o o India sales were~ 19,097 million, year-on-year growth of 65.3% International sales were~ 7,903 million, year-on-year growth of 0.6% • Earnings before Interest, Tax, Depreciation and Amortization (EBIT

0.6%

ion, year-on-year growth of 65.3% International sales were~ 7,903 million, year-on-year growth of 0.6% • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ~ 5,929 million, re

5,929 million

year growth of 0.6% • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ~ 5,929 million, resulting in EBITDA margin of 21.7% vs. 26.2% in Q1FY21. EBITDA grew by 13.6% YoY • R&D expens

21.7%

t, Tax, Depreciation and Amortization (EBITDA) was ~ 5,929 million, resulting in EBITDA margin of 21.7% vs. 26.2% in Q1FY21. EBITDA grew by 13.6% YoY • R&D expenses for the quarter was ~ 1,183 million,

26.2%

preciation and Amortization (EBITDA) was ~ 5,929 million, resulting in EBITDA margin of 21.7% vs. 26.2% in Q1FY21. EBITDA grew by 13.6% YoY • R&D expenses for the quarter was ~ 1,183 million, or 4.3% o

13.6%

TDA) was ~ 5,929 million, resulting in EBITDA margin of 21.7% vs. 26.2% in Q1FY21. EBITDA grew by 13.6% YoY • R&D expenses for the quarter was ~ 1,183 million, or 4.3% of total revenue from operations

1,183 million

argin of 21.7% vs. 26.2% in Q1FY21. EBITDA grew by 13.6% YoY • R&D expenses for the quarter was ~ 1,183 million, or 4.3% of total revenue from operations compared to~ 1,186 million in Q1FY21 at 6.0% of total r

Details of the conference call are as under

1

Dial in Details

1

Dial in Details

India : +91 22 6280 1149 / +91 22 7115 8050 International Toll Free USA UK Singapore Hong Kong : 1 866 746 2133 : 0 808 1011573 : 800 101 2045 : 800 964 448 Express Join with Diamond Pass https:/ /services. choruscall. in/Diamond PassRegistration/register?confirmation Nu mber-92 1173 7 &linkS ecu rityString=21a4976756 You are requested to dial in 10 mins ahead of the scheduled start time. A transcript of this conference call will also be available on our website www.alkemlabs.com About Alkem Laboratories Ltd. Established in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters : ALKE .NS) is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APls) and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800